Clinical Trial

An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis

Study acronym: dRAvite-LTE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will evaluate the long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with moderate to severe Rheumatoid Arthritis (RA) who have an inadequate response or intolerance to tumor necrosis factor (TNF) and/or Janus kinase (JAK) inhibitors, and who were previously treated with Afimkibart.
Protocol Amendment History 4 changes
notable Trial sites expanded: 1 -> 6 locations 2026-07-25
critical Recruitment opened 2026-06-27
notable Primary completion pushed: 2032-06-05 -> 2033-07-08 2026-06-27
minor Completion pushed: 2032-06-05 -> 2033-07-08 2026-06-27
Trial Details
NCT Number NCT07620392
Lead Sponsor Hoffmann-La Roche
Conditions Rheumatoid Arthritis
Enrollment 120 participants
Start Date 2026-06-03
Primary Completion 2033-07-08 (estimated)
Study Completion 2033-07-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-24